Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.37 |
| ▸ | VIPR2 | P41587 | 5/20 | 0.37 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.37 |
| ▸ | KRAS | P01116 | 5/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | TFPI | P10646 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2366970 | 1.00 | RXFP1 (0.41) | RXFP1NPY4RKEAP1PCSK9VIPR2 | |
| SCHEMBL2367433 | 0.96 | NPY4R (0.40) | RXFP1NPY4RKEAP1 | |
| SCHEMBL2367050 | 0.94 | RXFP1 (0.42) | RXFP1NPY4RVIPR2VIPR1TFPI | |
| SCHEMBL2367032 | 0.94 | RXFP1 (0.40) | RXFP1NPY4RKEAP1VIPR2VIPR1 | |
| SCHEMBL2367400 | 0.94 | RXFP1 (0.40) | RXFP1NPY4RKEAP1VIPR2VIPR1 | |
| SCHEMBL2368042 | 0.92 | RXFP1 (0.44) | RXFP1NPY4RKEAP1PCSK9 | |
| SCHEMBL2366814 | 0.91 | RXFP1 (0.42) | RXFP1NPY4RKEAP1KRAS | |
| SCHEMBL5073480 | 0.91 | NPY4R (0.47) | NPY4RKEAP1VIPR2VIPR1 | |
| SCHEMBL2367091 | 0.91 | RXFP1 (0.41) | RXFP1NPY4RKEAP1VIPR2VIPR1 | |
| SCHEMBL2367390 | 0.89 | RXFP1 (0.38) | RXFP1NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| EP-2007794-B1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO KG (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | RXFP1 355/4885NPY4R 1014/4885KEAP1 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.